U.S. Markets close in 56 mins.

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
54.24-1.74 (-3.11%)
As of 3:04PM EDT. Market open.
People also watch
Full screen
Previous Close55.98
Bid53.99 x 100
Ask54.01 x 1300
Day's Range52.06 - 54.44
52 Week Range46.01 - 76.48
Avg. Volume7,523,549
Market Cap89.36B
PE Ratio (TTM)18.84
Earnings DateN/A
Dividend & Yield1.56 (2.79%)
Ex-Dividend Date2017-07-05
1y Target EstN/A
Trade prices are not sourced from all markets
  • Did the Checkpoint Inhibitor Bubble Just Burst?
    Motley Fool2 hours ago

    Did the Checkpoint Inhibitor Bubble Just Burst?

    A failure in AstraZeneca's Mystic immuno-oncology drug trial sent shares of fellow cancer-fighters Agenus and Bristol-Myers Squibb tumbling Thursday.

  • Why Bristol-Myers Squibb Co (BMY) Shares Are Sinking Today
    InvestorPlace2 hours ago

    Why Bristol-Myers Squibb Co (BMY) Shares Are Sinking Today

    AstraZeneca plc (ADR)’s failed test was for lung cancer drug Imfinzi. The reason that this matters to BMY stock is because it has a similar drug in testing. Bristol-Myers Squibb Co is testing a combination of Opdivo and Yervoy. Credit Suisse analysts warn that the similarity between the two drug tests may tamper expectations for BMY’s efforts. The bad news for BMY stock came at the same time that it released its earnings report for the second quarter of 2017.

  • Reuters2 hours ago

    Bristol-Myers shares slump after failed AstraZeneca drug trial

    Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen. AstraZeneca's Mystic study, released Thursday, looked at a combination of immune system-boosting drugs to treat non-small cell lung cancer (NSCLC). Bristol-Myers is studying a similar combination of its two top drugs in the same therapy class, Opdivo and Yervoy.